HIV-1 p24 ELISA Kit (DEIA10155)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Species Reactivity
Intended Use
For the qualitative determination of HIV-1 p24 in samples.
Contents of Kit
1. Coated microwell strips: 1 plate (96 wells)
2. Positive p24 Control: 10 ng/mL, 0.1 mL
3. Lysis Buffer: 6 mL
4. Detector antibody anti-HIV-1 p24 conjugated to biotin: 12 mL
5. Conjugate: 12 mL
6. Wash Buffer (20x concentrated): 2 Bottles, 60 mL
7. Substrate Solution: 12 mL
8. Stop Solution: 1 N H2SO4, 12 mL
All reagents should be stored at 2-8°C, and should not be used beyond the expiration date on the label. Once opened, microtitration strips may be stored at 2-8°C until the expiration date on the label, provided that desiccated conditions are maintained. Unused strips should be returned to their original foil pouch along with the sachet of desiccant. Opened pouches should be securely resealed by folding over the open end and securing it with adhesive tape I.
The working strength Wash Buffer should not be stored for longer than 3 weeks at 2-8°C. It is recommended that Wash buffer be freshly diluted before each assay. If the working strength buffer becomes visibly cloudy or develops precipitate during the 3 weeks, do not use it.
Four samples with different levels of activity were assayed ten times each on three different assays. The results are summarized in the following table.
Precision Data:
To determine the sensitivity of the assay, the 0 standard was assayed 20 times. The minimal detectable level was calculated by adding two standard deviations to the mean absorbance for the 0 standard. The minimal detectable level is 1.7 pg/mL.
Standard Curve


Have you cited DEIA10155 in a publication? Let us know and earn a reward for your research.

Customer Reviews

Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket


Integrated Pharmacy and PrEP Navigation Services to Support PrEP Uptake: A Quality Improvement Project


Authors: Coleman, Megan; Hodges, Ashley; Henn, Sarah; Lambert, Crystal Chapman

Preexposure prophylaxis (PrEP) is highly effective in preventing HIV among both men and women, with the reduction in risk directly linked to medication adherence. Navigation services and other adherence interventions have demonstrated efficacy in medication uptake; however, their use may not be fully integrated into clinic operations or their roles clearly defined. This quality improvement (QI) project developed an evidenced-based PrEP Navigation (PN) tool to identify patient-reported barriers to uptake and to support process improvement at a large community health center in Washington, DC. Outcomes related to patient-reported barriers, patient demographics, and time to medication pickup from the pharmacy were measured before and after implementation. A total of 198 patients were included in this analysis. Mean days from initial prescription to medication pickup was reduced by 1.42 days (p = .030) following PN tool implementation. The evidenced-based PN tool is modifiable to the needs of the individual clinic and the patients they care for to support wide-scale PrEP uptake and continuous system process improvements.

E-cigarette Perceptions among HIV-positive Smokers in a Switching Study


Authors: Cioe, Patricia A.; Tidey, Jennifer W.; Mercurio, Alana N.; Costantino, Catherine; Kahler, Christopher W.

Objectives: Cigarette smoking is highly prevalent among persons with HIV (PWH), which is concerning due to their increased risk of developing smoking-related cancers compared to those without HIV. Smoking cessation rates are substantially lower among PWH compared to the general population and less than half report a goal of total abstinence. Given these factors, a switch to electronic cigarettes (ECs), as a form of tobacco harm reduction, may be a viable approach to decreasing tobacco-related morbidity and mortality in PWH. The US Food and Drug Administration has the authority to implement product standards for cigarettes, including ECs and flavors. Methods: This qualitative study enrolled 19 HIV-positive smokers into an EC switch study. At Week 12, qualitative interviews were conducted to examine EC perceptions and flavor preferences. Results: ECs were viewed as a less harmful, cost-effective method of reducing or eliminating CC smoking, and non-tobacco flavors were an essential part of EC appeal and use. Conclusions: Flavored EC liquid seems to enhance the user experience and may influence the user's ability to make a complete switch. Tobacco harm reduction, as a strategy, will only be effective if current evidence guides tobacco regulatory decisions.

Online Inquiry

Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:
Verification code
Click image to refresh the verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket